Current treatment strategies in elderly patients with metastatic colorectal cancer

被引：9

作者：

Arkenau, Hendrik-Tobias ^{[1
]}

Chua, Yu Jo ^{[1
]}

Cunningham, David ^{[1
]}

机构：

[1] Royal Marsden Hosp London & Sutton, Dept Med Oncol, Sutton SM2 5PT, Surrey, England

来源：

CLINICAL COLORECTAL CANCER | 2007年 / 6卷 / 07期

关键词：

chemotherapy; 5-fluorouracil; irinotecan; leucovorin; oxaliplatin;

D O I：

10.3816/CCC.2007.n.016

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Colorectal cancer (CRC) is one of the most common cancers in the Western world,with > 500,000 new cases diagnosed each year. One of the strongest risk factors for colon cancer is age. The incidence rates rise from 10 in 100,000 at age 40-45 years to 300 in 100,000 at age 75-80 years, with the median age at diagnosis of CRC being 71 years. With the general demographic shift toward an aging population, the number of people aged > 65 years is expected to increase. This article reviews the development of treatment for elderly patients with metastatic CRC, from single-agent fluoropyrimidines to combination therapies.

引用

页码：508 / 515

页数：8

共 55 条

[1] Oxaliplatin- or irinotecan-based chemotherapy for metastatic colorectal cancer in the elderly [J].

Aparicio, T ;

Desramé, J ;

Lecomte, T ;

Mitry, E ;

Belloc, J ;

Etienney, I ;

Montembault, S ;

Vayre, L ;

Locher, C ;

Ezenfis, J ;

Artru, P ;

Mabro, M ;

Dominguez, S .

BRITISH JOURNAL OF CANCER, 2003, 89 (08) :1439-1444

[2]

ARKENAU HT, 2007, 2007 GASTR CANC S JA

[3]

Balducci L, 2000, Oncologist, V5, P224, DOI 10.1634/theoncologist.5-3-224

[4]

BERETTA G, 1994, P AM SOC CLIN ONCOL, V13

[5]

BOLLINA R, 2003, P AN M AM SOC CLIN, V22, P332

[6] A randomized phase II trial of capecitabine and two different schedules of irinotecan in first-line treatment of metastatic colorectal cancer: efficacy, quality-of-life and toxicity [J].

Borner, MM ;

Bernhard, J ;

Dietrich, D ;

Popescu, R ;

Wernli, M ;

Saletti, P ;

Rauch, D ;

Herrmann, R ;

Koeberle, D ;

Honegger, H ;

Brauchli, P ;

Lanz, D ;

Roth, AD .

ANNALS OF ONCOLOGY, 2005, 16 (02) :282-288

[7]

Brink T.A., 1982, CLIN GERONTOLOGIST, V1, P37, DOI [10.1300/J018v01n01_06, DOI 10.1300/J018V01N01_06]

[8]

CASSIDY J, 2007, 2007 GASTR CANC S JA

[9] Elderly patients with fluoropyrimidine and thymidylate synthase inhibitor-resistant advanced colorectal cancer derive similar benefit without excessive toxicity when treated with irinotecan monotherapy [J].

Chau, I ;

Norman, AR ;

Cunningham, D ;

Waters, JS ;

Topham, C ;

Middleton, G ;

Hill, M ;

Ross, PJ ;

Katopodis, R ;

Stewart, G ;

Oates, JR .

BRITISH JOURNAL OF CANCER, 2004, 91 (08) :1453-1458

[10]

Colorectal Canc Collaborative Grp, 2000, BMJ-BRIT MED J, V321, P531

← 1 2 3 4 5 6 →